Amendments to the Claims:

What is claimed is:

1. (Currently Amended) A method of treating cardiotoxicity and hypertension induced by a vascular targeting agent, ~~treatment of a disease state associated with Vascular Targeting~~ comprising ~~the administration of an effective amount of a~~ administering said [[V]]vascular [[T]]targeting [[A]]agent ~~and~~ in combination with an [[A]]anti-[[H]]hypertensive [[A]]agent to a mammal, wherein said vascular targeting agent is selected from the group consisting of a combretastatin, combretastatin A-4 phosphate, a combretastatin A-1 diphosphate, or a pharmaceutically acceptable salt thereof and further wherein said anti-hypertensive agent is a vasodilator.

2. (Canceled)

3. (Currently Amended) The method of claim 1, wherein said [[V]]vascular [[T]]targeting [[A]]agent is selected from the group consisting of Combretastatin A-4 Phosphate, Combretastatin A-1 Diphosphate, and a pharmaceutically acceptable salt thereof.

4. (Canceled)

5. (Canceled)

6. (CurrentlyAmended) The method of claim [[4]]17, wherein said [[V]]vasodilator is nitroglycerin ~~or a derivative thereof~~.

7. (Canceled)

8. (Canceled)

9.-14. (Canceled)

15. (Currently Amended) The method of claim [[3]]1, wherein said pharmaceutically acceptable salt is a sodium salt or a triethylamine salt.

16. (Canceled)

17. (Currently Amended) The method of claim [[4]]1, wherein said vasodilator is selected from the group consisting of isosobide mononitrate, isosorbide dinitrate, nitroglycerin, fenoldopam mesylate, epoprostenol sodium, milrinone lactate, and sodium nitroprusside.

18. (Currently Amended) The method of claim 1, wherein said vascular targeting agent is combretastatin A-4 disodium phosphate.

19. (Canceled)

20. (Canceled)

21. (Previously Presented) The method of claim 1, wherein said vascular targeting agent is combretastatin A-1 tetrasodium diphosphate.

22. (Canceled)

23. (Previously Presented) The method of claim 21, wherein said antihypertensive agent is nitroglycerin.

24. (Currently Amended) The method of claim [[2]]1, wherein said ~~combretastatin, Combretastatin analog, and~~ vascular targeting agent or a pharmaceutically acceptable salt thereof, is administered at a dosage of 100 mg/kg or less.

25. (Currently Amended) The method of claim 1, wherein said vascular targeting agent or a pharmaceutically acceptable salt thereof is administered intravenously.

26.-28. (Canceled)

29. (Previously Presented) The method of claim 1, wherein said anti-hypertensive agent is administered simultaneously with said vascular targeting agent.

30. (Previously Presented) The method of claim 1, wherein said anti-hypertensive agent is administered prior to the administration of said vascular targeting agent.

31. (Previously Presented) The method of claim 1, wherein said anti-hypertensive agent is administered following the administration of said vascular targeting agent.

32. (Previously Presented) The method of claim 1, wherein said vascular targeting agent is being chronically administered to said animal.

33. (Withdrawn) A method for reducing the hypertensive effect of a vascular targeting agent administered to a warm-blooded animal, said method comprising administering to said animal an effective amount of a vascular targeting agent and an anti-hypertensive agent.

34. (Withdrawn) The method of claim 33, wherein said Vascular Targeting Agent is selected from the group consisting of a Combretastatin, a Combretastatin analog, and a pharmaceutically acceptable salt thereof.

35. (Withdrawn) The method of claim 33, wherein said Vascular Targeting Agent is selected from the group consisting of Combretastatin A-4 Phosphate, Combretastatin A-l Diphosphate, and a pharmaceutically acceptable salt thereof.

36. (Withdrawn) The method of claim 33, wherein said Anti-Hypertensive Agent is a Beta Blocker or a Vasodilator.

37. (Withdrawn) The method of claim 36, wherein said Beta Blocker is Propanolol or a derivative thereof.

38. (Withdrawn) The method of claim 36, wherein said Vasodilator is nitroglycerin or a derivative thereof.

39. (Withdrawn) The method of claim 35, wherein said pharmaceutically acceptable salt is a sodium salt or a triethylamine salt.

40. (Withdrawn) The method of claim 36, wherein said beta-blocker is selected from the group consisting of timolol maleate, cateolol hydrochloride, carvedilol, betaxolol hydrochloride, 1-(tert-butyl-amino)3-[(5,6,7,8-tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy]-2-propanolol, labetalol hydrochloride, acebutolol hydrochloride, atenolol, metoprolol succinate, bisopropolol, esmolol hydrochloride, and propanolol.

41. (Withdrawn) The method of claim 36, wherein said vasodilator is selected from the group consisting of isosobide mononitrate, isosorbide dinitrate, nitroglycerin, fenoldopam mesylate, epoprostenol sodium, milrinone lactate, and sodium nitroprusside.

42. (Withdrawn) The method of claim 33, wherein said vascular targeting agent is combretastatin A-4 disodium phosphate.

43. (Withdrawn) The method of claim 42, wherein said antihypertensive agent is propanolol.

44. (Withdrawn) The method of claim 42, wherein said antihypertensive agent is nitroglycerin.

45. (Withdrawn) The method of claim 33, wherein said vascular targeting agent is combretastatin A-1 tetrasodium diphosphate.

46. (Withdrawn) The method of claim 45, wherein said antihypertensive agent is propanolol.

47. (Withdrawn) The method of claim 45, wherein said antihypertensive agent is nitroglycerin.

48. (Withdrawn) The method of claim 34, wherein said combretastatin is administered at a dosage of 100 mg/kg or less.

49. (Withdrawn) The method of claim 33, wherein said vascular targeting agent is administered intravenously.

50. (Withdrawn) The method of claim 33, wherein said anti-hypertensive agent is administered simultaneously with said vascular targeting agent.

51. (Withdrawn) The method of claim 33, wherein said anti-hypertensive agent is administered prior to the administration of said vascular targeting agent.

52. (Withdrawn) The method of claim 33, wherein said anti-hypertensive agent is administered following the administration of said vascular targeting agent.

53. (Withdrawn) The method of claim 33, wherein said vascular targeting agent is being chronically administered to said animal.